YH001 + envafolimab

**YH001 + envafolimab** is a combination of two antibody-based immunotherapies, investigated for the treatment of advanced or metastatic sarcoma. YH001 is an IgG1 monoclonal antibody that targets CTLA-4, designed to enhance anti-tumor immune responses through T cell activation and regulatory T cell depletion. It displays enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) compared to ipilimumab in preclinical studies. Envafolimab (KN035) is a humanized single-domain antibody against PD-L1, forming a fusion protein with a mutated IgG1 Fc fragment, engineered for subcutaneous administration. Envafolimab inhibits PD-L1-mediated immune suppression, promoting T cell activation against tumor cells. Envafolimab is approved in China for MSI-H/dMMR advanced solid tumors and has demonstrated efficacy and safety in clinical trials of various cancers. The combination of YH001 and envafolimab is being studied in a multicenter Phase 1/2 trial for advanced or metastatic sarcoma, including alveolar soft part sarcoma, chondrosarcoma, leiomyosarcoma, and dedifferentiated liposarcoma[1][3][5].

Other names

YH001YH-001YH 001envafolimabKN035KN-035KN 035